Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Average Recommendation of “Reduce” by Brokerages

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have been given a consensus rating of “Reduce” by the eleven brokerages that are currently covering the company, Marketbeat reports. Five analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $23.5667.

A number of research analysts recently issued reports on the stock. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Truist Financial set a $25.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Sanford C. Bernstein increased their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research report on Thursday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 4th.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Hedge funds have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares during the period. Arax Advisory Partners grew its position in Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after purchasing an additional 885 shares during the period. Kestra Advisory Services LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at $58,000. Finally, Group One Trading LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at $74,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.2%

Shares of FMS stock opened at $24.33 on Thursday. The company has a market cap of $13.07 billion, a P/E ratio of 12.61, a PEG ratio of 4.28 and a beta of 0.77. The stock has a 50 day simple moving average of $23.65 and a two-hundred day simple moving average of $23.05. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. The firm had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. Research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.